Squamous cell lung cancer (SqCLC), which accounts for approximately 25% to 30% of all lung cancer cases, is the second-most prevalent histologic subtype of NSCLC. Its distinct clinicopathologic and molecular […] Read more
By Kara Nyberg, PhD Posted: April 16, 2020 After decades of failed clinical trials and persistently dismal lung cancer survival outcomes, the 2010s breathed new life into the beleaguered field […] Read more
By Sylvie Lantuejoul, MD, PhD, and Mari Mino-Kenudson, MD Posted: April 16, 2020 Immune checkpoint inhibitors (ICI), which target the PD-1/PD-L1 axis with the aim of restoring anti-tumor immunity, are […] Read more
By Neal Ready, MD, PhD Posted: February 12, 2020 Dr. Neal Ready Programmed death receptor (PD-1) checkpoint monoclonal antibody therapy has proven a major advancement in the management of advanced […] Read more
By Anjali Saqi, MD, MBA; Deepali Jain, MD, FIAC; Lukas Bubendorf, MD; Keith Kerr, MB, ChB, MRCPath, FRCPath, FRCP(Ed); and Andre Moreira, MD, PhD Posted: December 11, 2019 Lung cancer […] Read more
Posted: November 12, 2019 Now that data from the PACIFIC trial have been incorporated into daily practice, similar trials are validating the results or taking PACIFIC data in new directions. […] Read more
By Mari Mino-Kenudson, MD, and Sylvie Lantuejoul, MD, PhD Posted: November 12, 2019 Determination of PD-L1 expression by immunohistochemistry (IHC) has been widely evaluated in clinical trials as a predictive […] Read more